Ann: Investor Presentation, page-7

I stand corrected. My understanding was that conventional external scans could show much of the detail required for initial diagnosis at least.  Thanks for the information. 

That said, I still think that mobile (+ non-invasive) is a very strong driver that would be most compelling for first product markets.
I have worked in product development for a long time and the most successful first products in biomedical spaces are ones that obviously and undeniably fill an urgent need and make/save significant money.
The reason is that the medical community are naturally risk averse an there is a large entropy barrier for new technologies. Even if product efficacy is proven, many health professionals will stick with what they already know until there is an overwhelming argument to change. Add that to regulatory approval requirements and it is no wonder developing biomedical products can be an expensive and long road.

Just my ramblings though. The team behind this have a good track record so I bought a small parcel based on that and will be ready to be surprised and delighted.
GLTAH